Novartis Produces H1N1 Vaccine in the Midst of Pandemic Declaration

Swiss pharmaceuticals company Novartis had finally developed the first batch of its Influenza A (H1N1) vaccine weeks ahead of expectation. Experts say that after clinical testing the new vaccine will be available for the public consumption by September. The only worry is the fact that from today to September there might be new developments on this new strain of the virus.

Novartis said it would use the first batch of vaccine for pre-clinical evaluation and testing. It is also being considered for clinical trials, the company said. The vaccine was produced at a Novartis plant in Marburg, Germany. Novartis said the facility could potentially produce millions of doses of vaccine a week.

Novartis said more than 30 governments have requested vaccine supplies, including the U.S. Department of Health and Human Service, which placed a $289 million order in May.



Also Visit My Other Blogs
| Pagod Ka Na Bang Maging si Juan? | Ordinary People, Ordinary Day |